Published in Lab Business Week, May 6th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Dynavax Technologies Corporation.
Report 1: Dynavax Technologies Corporation (NASDAQ:DVAX) announced that it had initiated a Phase 1 trial of its novel therapy for chronic hepatitis B virus (HBV) infection. The trial is being conducted in Hamburg, Germany and will enroll 20 healthy subjects to evaluate the safety of the therapy at two dosing schedules. The novel HBV therapy combines, for the first time, the surface and core antigen of HBV, manufactured at Dynavax Europe....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week